The document discusses the impact of Denmark's national oxygen register on adherence to guidelines for long-term oxygen therapy (LTOT) in COPD patients. Some key findings from 1994-2000 include an increase in the prevalence and incidence of COPD patients on LTOT, more patients receiving mobile oxygen and starting LTOT after hospitalization. Documentation of hypoxemia improved but only about half of patients received follow-up and 20-25% still smoked. Survival rates increased over time but remained lower than other countries. The register data was not optimally utilized and direct feedback to doctors may help further improve LTOT guideline adherence.
The document discusses loading patterns on ship structures during grounding incidents based on analyses of past cases. It finds that bottom structures experience complex loading over extended periods, not just initially. Loading depends on seafloor conditions and impact angle. Past incidents show bottom tearing up to 5m deep, transverse frame deformation up to 8m wide, and damage extending over 100s of meters. Loading causes buckling, breaches of tanks and hull, and fracturing of bulkheads. The document concludes bottom structures face varying loads that are difficult to model and can damage ships for days after the initial impact.
This document summarizes findings from the Danish Oxygen Register regarding long-term oxygen therapy (LTOT) in Denmark from 1994-2000. Some key findings include:
- The prevalence and incidence of COPD patients on LTOT increased and reached a plateau around 25 and 40 per 100,000 respectively.
- There was an increase in the proportion of cancer patients, older patients, and those using mobile oxygen units starting LTOT. The percentage treated over 15 hours daily and after hospital admission also rose.
- Around 20-25% of COPD patients on LTOT were still smoking despite the therapy.
- Survival rates improved over the period, however remained lower than other countries due to higher 6-
This document discusses home oxygen treatment. It provides an overview of the scientific evidence for indications and effects of oxygen therapy. It also reviews prevalence, devices, side effects, and practical considerations for home oxygen treatment in Denmark. A case study is presented on whether a 65-year-old woman with COPD exacerbation should start chronic oxygen therapy. Guidelines for initiating oxygen are outlined. Survival rates on oxygen are compared between countries.
Teens and young adults are increasingly using electronic cigarettes, but little is known about the long-term cardiopulmonary health effects of these nicotine-delivery devices.
During this webinar, Jason Gardner, PhD, presents his latest findings using a mouse model of chronic, inhaled nicotine exposure. Post-exposure to nicotine caused mice to develop pulmonary hypertension (PH) and right ventricular (RV) remodeling, a phenomenon that is prevented using an angiotensin II type I receptor (AT1) blocker, losartan. Dr. Gardner discusses the details of this work and how the renin-angiotensin system plays a key role in PH and RV remodeling. In addition, he expands upon the current research with new, unpublished findings.
For more information or to watch the webinar, visit https://bit.ly/3guetlr
1. Yes, the patient meets the criteria for home oxygen therapy with a PO2 <7.3 kPa at rest.
2. Portable oxygen for mobile hypoxemic patients is intended to:
- Increase hours on oxygen
- Increase daily activity
3. Studies have found no effect of adding ambulatory oxygen to pulmonary rehabilitation programs. Ambulatory oxygen alone does not improve exercise tolerance long-term.
1) Home oxygen therapy (HOT) improves survival in patients with hypoxemia, though adherence to guidelines and follow-up is only about 50% in many countries.
2) Continuous oxygen therapy (COT) given for over 15 hours daily increases survival by 2-4 years in COPD patients with low oxygen levels. Portable oxygen allows more activity but devices are still heavy.
3) International guidelines recommend COT for patients with oxygen levels below 7.3 kPa, but adherence varies, from 35-81% of eligible patients receiving treatment across different countries. Follow-up after starting COT is also inconsistent.
Venous and arterial blood gas analysis in the ED: What we know and what we don'tkellyam18
This presentation delivered at the International Conference on Emergency Medicine in Dublin summarises agreement between venous and arterial blood gas parameters and utility of venous blood gas analysis in emergency department clinical practice. It also highlights important gaps in our knowledge on this topic.
This document discusses home oxygen therapy (HOT) in various countries. It provides an overview of the types of HOT, including continuous oxygen therapy (COT), short-term oxygen therapy (STOT), and nocturnal oxygen therapy (NOT). Clinical trials show that COT improves survival in COPD patients with low oxygen levels. Guidelines for COT recommend a minimum daily usage of 15 hours and follow-up every 3-6 months. Adherence to HOT varies significantly between countries, from 60% in Denmark to rates as low as 27% in some studies. Portable oxygen improves mobility and activity levels but is underutilized in many patients.
The document discusses loading patterns on ship structures during grounding incidents based on analyses of past cases. It finds that bottom structures experience complex loading over extended periods, not just initially. Loading depends on seafloor conditions and impact angle. Past incidents show bottom tearing up to 5m deep, transverse frame deformation up to 8m wide, and damage extending over 100s of meters. Loading causes buckling, breaches of tanks and hull, and fracturing of bulkheads. The document concludes bottom structures face varying loads that are difficult to model and can damage ships for days after the initial impact.
This document summarizes findings from the Danish Oxygen Register regarding long-term oxygen therapy (LTOT) in Denmark from 1994-2000. Some key findings include:
- The prevalence and incidence of COPD patients on LTOT increased and reached a plateau around 25 and 40 per 100,000 respectively.
- There was an increase in the proportion of cancer patients, older patients, and those using mobile oxygen units starting LTOT. The percentage treated over 15 hours daily and after hospital admission also rose.
- Around 20-25% of COPD patients on LTOT were still smoking despite the therapy.
- Survival rates improved over the period, however remained lower than other countries due to higher 6-
This document discusses home oxygen treatment. It provides an overview of the scientific evidence for indications and effects of oxygen therapy. It also reviews prevalence, devices, side effects, and practical considerations for home oxygen treatment in Denmark. A case study is presented on whether a 65-year-old woman with COPD exacerbation should start chronic oxygen therapy. Guidelines for initiating oxygen are outlined. Survival rates on oxygen are compared between countries.
Teens and young adults are increasingly using electronic cigarettes, but little is known about the long-term cardiopulmonary health effects of these nicotine-delivery devices.
During this webinar, Jason Gardner, PhD, presents his latest findings using a mouse model of chronic, inhaled nicotine exposure. Post-exposure to nicotine caused mice to develop pulmonary hypertension (PH) and right ventricular (RV) remodeling, a phenomenon that is prevented using an angiotensin II type I receptor (AT1) blocker, losartan. Dr. Gardner discusses the details of this work and how the renin-angiotensin system plays a key role in PH and RV remodeling. In addition, he expands upon the current research with new, unpublished findings.
For more information or to watch the webinar, visit https://bit.ly/3guetlr
1. Yes, the patient meets the criteria for home oxygen therapy with a PO2 <7.3 kPa at rest.
2. Portable oxygen for mobile hypoxemic patients is intended to:
- Increase hours on oxygen
- Increase daily activity
3. Studies have found no effect of adding ambulatory oxygen to pulmonary rehabilitation programs. Ambulatory oxygen alone does not improve exercise tolerance long-term.
1) Home oxygen therapy (HOT) improves survival in patients with hypoxemia, though adherence to guidelines and follow-up is only about 50% in many countries.
2) Continuous oxygen therapy (COT) given for over 15 hours daily increases survival by 2-4 years in COPD patients with low oxygen levels. Portable oxygen allows more activity but devices are still heavy.
3) International guidelines recommend COT for patients with oxygen levels below 7.3 kPa, but adherence varies, from 35-81% of eligible patients receiving treatment across different countries. Follow-up after starting COT is also inconsistent.
Venous and arterial blood gas analysis in the ED: What we know and what we don'tkellyam18
This presentation delivered at the International Conference on Emergency Medicine in Dublin summarises agreement between venous and arterial blood gas parameters and utility of venous blood gas analysis in emergency department clinical practice. It also highlights important gaps in our knowledge on this topic.
This document discusses home oxygen therapy (HOT) in various countries. It provides an overview of the types of HOT, including continuous oxygen therapy (COT), short-term oxygen therapy (STOT), and nocturnal oxygen therapy (NOT). Clinical trials show that COT improves survival in COPD patients with low oxygen levels. Guidelines for COT recommend a minimum daily usage of 15 hours and follow-up every 3-6 months. Adherence to HOT varies significantly between countries, from 60% in Denmark to rates as low as 27% in some studies. Portable oxygen improves mobility and activity levels but is underutilized in many patients.
COPD AND ICU MANAGEMENT : DR DEVAWRAT BUCHEDevawrat Buche
COPD is a common preventable disease characterized by persistent airflow limitation associated with chronic inflammation in the airways and lungs due to noxious particles. The severity of COPD is assessed using symptoms, spirometry results, exacerbation risk, and comorbidities. Treatment involves smoking cessation, pharmacotherapy including bronchodilators and inhaled corticosteroids, rehabilitation, vaccination, and management of exacerbations with oxygen therapy, bronchodilators, corticosteroids, and antibiotics.
This document provides an overview of chronic obstructive pulmonary disease (COPD) including objectives, anatomy, pathophysiology, diagnostic tests, medical management, nursing diagnoses, and patient teaching. It discusses COPD, defining it as a chronic lung disease including chronic bronchitis and emphysema. A case study is presented of a 55-year-old female with shortness of breath and a history of COPD exacerbated by minor exertion. Nursing management focuses on oxygen therapy, airway clearance techniques, activity pacing, vaccination, smoking cessation counseling and pulmonary rehabilitation.
This document summarizes a meeting of the Asthma-COPD Overlap Working Group. The group discussed current and future projects on defining and studying Asthma-COPD Overlap (ACO). Their current project examines how ACO prevalence varies depending on the population definition used within a UK database. Future projects proposed examining ACO definitions across other databases and comparing outcomes for patients with ACO versus COPD. The group prioritized repeating their analyses in other databases as Phase 1 and studying patient outcomes as Phase 2. They discussed logistics of sharing data and analysis scripts between researchers.
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...brnmomentum
1) The PROMETE II study was a randomized controlled trial evaluating the use of home telemonitoring (HTM) compared to routine clinical practice (RCP) in elderly patients with severe COPD requiring long-term oxygen therapy.
2) The primary outcome of reducing hospitalizations and emergency room visits was not significantly different between the HTM and RCP groups.
3) However, the duration of hospital stays appeared to be shorter in the HTM group, with the mean duration of hospitalization being approximately 4 days less, though this was not statistically significant.
This document provides guidelines for the management of chronic obstructive pulmonary disease (COPD). It discusses assessing and monitoring the disease severity using spirometry tests and classifications. It recommends reducing risk factors like smoking and managing stable COPD with bronchodilators, inhaled steroids, oxygen therapy, and exercise training. For exacerbations, it suggests treating with inhaled bronchodilators, oral steroids, antibiotics if infected, and noninvasive ventilation.
This document discusses chronic obstructive pulmonary disease (COPD) and its management in primary care. It begins by outlining the burden of COPD as a leading cause of morbidity and mortality worldwide. It then defines COPD and describes its pathophysiology, risk factors, clinical progression, diagnosis through symptoms, signs and spirometry testing, and methods to distinguish it from asthma. The document discusses assessing COPD severity, symptoms, and exacerbation risk. It outlines the goals of COPD therapy in managing stable disease and exacerbations. Specific drug classes used to control COPD symptoms are identified. Combination short-acting bronchodilators are recommended for initial treatment, and studies showing their benefits over monotherapy in outcomes are summarized
The latest guidelines on the management of a COPD patient ( Stable COPD, patient with an exacerbation of COPD), latest modalities of treatment of a COPD patient
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a progressive lung disease characterized by limited airflow. The two major types are chronic bronchitis and emphysema. Risk factors include smoking, air pollution, and aging. Symptoms include chronic cough, shortness of breath, and limited activity. Treatment focuses on bronchodilators, steroids, oxygen therapy, and smoking cessation. Proper management can control symptoms and reduce exacerbations.
Ipertensione Polomonare nelle malattie polmonariPAH-GHIO
The document discusses pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILDs) such as idiopathic pulmonary fibrosis (IPF). It summarizes findings from studies on the prevalence and impact of PH in these conditions. It also reviews potential treatments for PH in COPD/ILD, including vasodilator therapies such as sildenafil, bosentan, and iloprost, though evidence of benefit is limited. Precise definitions and screening are needed to identify patients with disproportionate PH who may warrant more aggressive management.
The document provides guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD) from the European Respiratory Society and American Thoracic Society. It aims to improve COPD patient care, promote a disease-oriented approach, and be updated based on new evidence. The guidelines cover defining COPD, epidemiology, pathogenesis, diagnosis, management of stable COPD including pharmacological therapies, pulmonary rehabilitation, and smoking cessation.
This document discusses COPD (chronic obstructive pulmonary disease) and the potential role of telemonitoring in its management. It defines COPD as including asthma, chronic bronchitis, and emphysema. Telemonitoring allows for remote monitoring of COPD patients using devices that transmit health data. It is suggested that telemonitoring may help with earlier detection of exacerbations through reported symptoms. It could also increase disease knowledge and self-care, provide reassurance and support, and reduce hospital admissions. Several studies found telemonitoring improved quality of life and reduced costs, though the evidence base is still developing.
Severe Asthma/Biomarkers Working Group ERS 2017Kathryn Brown
The document summarizes a meeting of the Severe Asthma/Biomarkers Joint Working Group. It includes an agenda for presentations on recent and ongoing projects related to using biomarkers like FeNO and blood eosinophils to predict outcomes in severe asthma. Presentations covered recent publications on these topics, updates on registry initiatives like ISAR and available data sources like OPCRD, and ideas for new projects. Attendees also discussed previous ideas around further evaluating biomarkers as predictors of treatment response and clinical outcomes.
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a progressive lung disease characterized by limited airflow. The two major types are chronic bronchitis and emphysema. Risk factors include smoking, air pollution, and genetics. Symptoms include chronic cough, shortness of breath, and limited activity. Treatment focuses on bronchodilators, steroids, oxygen therapy, and smoking cessation. Proper diagnosis and use of evidence-based guidelines can help control symptoms and reduce exacerbations.
The document provides information on chronic obstructive pulmonary disease (COPD) from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). It defines COPD as a common preventable disease characterized by persistent airflow limitation associated with an enhanced inflammatory response in the airways. It discusses mechanisms of airflow limitation, risk factors, assessment of COPD including symptoms, spirometry and exacerbation history, management of stable COPD and exacerbations, and pharmacologic treatment options.
This document provides an overview of Chronic Obstructive Pulmonary Disease (COPD), including its definition, risk factors, pathophysiology, diagnosis, assessment, management, and anesthetic considerations. It discusses the two main components of COPD, chronic bronchitis and emphysema, and how they differ. It outlines the old and new GOLD criteria for classifying COPD severity. Management involves addressing risk factors, pharmacotherapy including bronchodilators, and treating exacerbations. Anesthetic management of COPD patients requires consideration of their airflow limitation and comorbidities.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide. It is characterized by persistent respiratory symptoms and airflow limitation caused by exposure to noxious particles or gases. A diagnosis of COPD requires risk factors like smoking, symptoms like dyspnea, and spirometry showing post-bronchodilator FEV1/FVC < 0.70. Acute exacerbations of COPD (AeCOPD) are defined as acute worsening of respiratory symptoms and are classified based on severity of symptoms and oxygen levels. Treatment depends on a patient's clinical phenotype and exacerbation history.
A 62-year-old woman with a 40 pack-year smoking history presented with chronic cough for 3 months, producing clear to light yellow sputum. On examination, she had rhonchi breath sounds and 1+ ankle edema. Tests showed an FEV1/FVC ratio of 0.60 and FEV1 of 55%, consistent with a diagnosis of moderate COPD.
A 54-year-old man with an 80+ pack-year smoking history presented with dyspnea on exertion and occasional non-productive cough. Examination found diminished breath sounds and prolonged expiratory phase. Tests showed an FEV1/FVC ratio of 0.55 and FEV1 of 40%, consistent with severe
The document discusses guidelines for managing chronic obstructive pulmonary disease (COPD). It describes COPD as a chronic inflammatory lung disease characterized by airflow limitation. The guidelines recommend treatments based on COPD severity, including bronchodilators and inhaled corticosteroids. Ongoing research is exploring new drugs and combinations to better treat COPD and reduce exacerbations.
COPD AND ICU MANAGEMENT : DR DEVAWRAT BUCHEDevawrat Buche
COPD is a common preventable disease characterized by persistent airflow limitation associated with chronic inflammation in the airways and lungs due to noxious particles. The severity of COPD is assessed using symptoms, spirometry results, exacerbation risk, and comorbidities. Treatment involves smoking cessation, pharmacotherapy including bronchodilators and inhaled corticosteroids, rehabilitation, vaccination, and management of exacerbations with oxygen therapy, bronchodilators, corticosteroids, and antibiotics.
This document provides an overview of chronic obstructive pulmonary disease (COPD) including objectives, anatomy, pathophysiology, diagnostic tests, medical management, nursing diagnoses, and patient teaching. It discusses COPD, defining it as a chronic lung disease including chronic bronchitis and emphysema. A case study is presented of a 55-year-old female with shortness of breath and a history of COPD exacerbated by minor exertion. Nursing management focuses on oxygen therapy, airway clearance techniques, activity pacing, vaccination, smoking cessation counseling and pulmonary rehabilitation.
This document summarizes a meeting of the Asthma-COPD Overlap Working Group. The group discussed current and future projects on defining and studying Asthma-COPD Overlap (ACO). Their current project examines how ACO prevalence varies depending on the population definition used within a UK database. Future projects proposed examining ACO definitions across other databases and comparing outcomes for patients with ACO versus COPD. The group prioritized repeating their analyses in other databases as Phase 1 and studying patient outcomes as Phase 2. They discussed logistics of sharing data and analysis scripts between researchers.
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...brnmomentum
1) The PROMETE II study was a randomized controlled trial evaluating the use of home telemonitoring (HTM) compared to routine clinical practice (RCP) in elderly patients with severe COPD requiring long-term oxygen therapy.
2) The primary outcome of reducing hospitalizations and emergency room visits was not significantly different between the HTM and RCP groups.
3) However, the duration of hospital stays appeared to be shorter in the HTM group, with the mean duration of hospitalization being approximately 4 days less, though this was not statistically significant.
This document provides guidelines for the management of chronic obstructive pulmonary disease (COPD). It discusses assessing and monitoring the disease severity using spirometry tests and classifications. It recommends reducing risk factors like smoking and managing stable COPD with bronchodilators, inhaled steroids, oxygen therapy, and exercise training. For exacerbations, it suggests treating with inhaled bronchodilators, oral steroids, antibiotics if infected, and noninvasive ventilation.
This document discusses chronic obstructive pulmonary disease (COPD) and its management in primary care. It begins by outlining the burden of COPD as a leading cause of morbidity and mortality worldwide. It then defines COPD and describes its pathophysiology, risk factors, clinical progression, diagnosis through symptoms, signs and spirometry testing, and methods to distinguish it from asthma. The document discusses assessing COPD severity, symptoms, and exacerbation risk. It outlines the goals of COPD therapy in managing stable disease and exacerbations. Specific drug classes used to control COPD symptoms are identified. Combination short-acting bronchodilators are recommended for initial treatment, and studies showing their benefits over monotherapy in outcomes are summarized
The latest guidelines on the management of a COPD patient ( Stable COPD, patient with an exacerbation of COPD), latest modalities of treatment of a COPD patient
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a progressive lung disease characterized by limited airflow. The two major types are chronic bronchitis and emphysema. Risk factors include smoking, air pollution, and aging. Symptoms include chronic cough, shortness of breath, and limited activity. Treatment focuses on bronchodilators, steroids, oxygen therapy, and smoking cessation. Proper management can control symptoms and reduce exacerbations.
Ipertensione Polomonare nelle malattie polmonariPAH-GHIO
The document discusses pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILDs) such as idiopathic pulmonary fibrosis (IPF). It summarizes findings from studies on the prevalence and impact of PH in these conditions. It also reviews potential treatments for PH in COPD/ILD, including vasodilator therapies such as sildenafil, bosentan, and iloprost, though evidence of benefit is limited. Precise definitions and screening are needed to identify patients with disproportionate PH who may warrant more aggressive management.
The document provides guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD) from the European Respiratory Society and American Thoracic Society. It aims to improve COPD patient care, promote a disease-oriented approach, and be updated based on new evidence. The guidelines cover defining COPD, epidemiology, pathogenesis, diagnosis, management of stable COPD including pharmacological therapies, pulmonary rehabilitation, and smoking cessation.
This document discusses COPD (chronic obstructive pulmonary disease) and the potential role of telemonitoring in its management. It defines COPD as including asthma, chronic bronchitis, and emphysema. Telemonitoring allows for remote monitoring of COPD patients using devices that transmit health data. It is suggested that telemonitoring may help with earlier detection of exacerbations through reported symptoms. It could also increase disease knowledge and self-care, provide reassurance and support, and reduce hospital admissions. Several studies found telemonitoring improved quality of life and reduced costs, though the evidence base is still developing.
Severe Asthma/Biomarkers Working Group ERS 2017Kathryn Brown
The document summarizes a meeting of the Severe Asthma/Biomarkers Joint Working Group. It includes an agenda for presentations on recent and ongoing projects related to using biomarkers like FeNO and blood eosinophils to predict outcomes in severe asthma. Presentations covered recent publications on these topics, updates on registry initiatives like ISAR and available data sources like OPCRD, and ideas for new projects. Attendees also discussed previous ideas around further evaluating biomarkers as predictors of treatment response and clinical outcomes.
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a progressive lung disease characterized by limited airflow. The two major types are chronic bronchitis and emphysema. Risk factors include smoking, air pollution, and genetics. Symptoms include chronic cough, shortness of breath, and limited activity. Treatment focuses on bronchodilators, steroids, oxygen therapy, and smoking cessation. Proper diagnosis and use of evidence-based guidelines can help control symptoms and reduce exacerbations.
The document provides information on chronic obstructive pulmonary disease (COPD) from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). It defines COPD as a common preventable disease characterized by persistent airflow limitation associated with an enhanced inflammatory response in the airways. It discusses mechanisms of airflow limitation, risk factors, assessment of COPD including symptoms, spirometry and exacerbation history, management of stable COPD and exacerbations, and pharmacologic treatment options.
This document provides an overview of Chronic Obstructive Pulmonary Disease (COPD), including its definition, risk factors, pathophysiology, diagnosis, assessment, management, and anesthetic considerations. It discusses the two main components of COPD, chronic bronchitis and emphysema, and how they differ. It outlines the old and new GOLD criteria for classifying COPD severity. Management involves addressing risk factors, pharmacotherapy including bronchodilators, and treating exacerbations. Anesthetic management of COPD patients requires consideration of their airflow limitation and comorbidities.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide. It is characterized by persistent respiratory symptoms and airflow limitation caused by exposure to noxious particles or gases. A diagnosis of COPD requires risk factors like smoking, symptoms like dyspnea, and spirometry showing post-bronchodilator FEV1/FVC < 0.70. Acute exacerbations of COPD (AeCOPD) are defined as acute worsening of respiratory symptoms and are classified based on severity of symptoms and oxygen levels. Treatment depends on a patient's clinical phenotype and exacerbation history.
A 62-year-old woman with a 40 pack-year smoking history presented with chronic cough for 3 months, producing clear to light yellow sputum. On examination, she had rhonchi breath sounds and 1+ ankle edema. Tests showed an FEV1/FVC ratio of 0.60 and FEV1 of 55%, consistent with a diagnosis of moderate COPD.
A 54-year-old man with an 80+ pack-year smoking history presented with dyspnea on exertion and occasional non-productive cough. Examination found diminished breath sounds and prolonged expiratory phase. Tests showed an FEV1/FVC ratio of 0.55 and FEV1 of 40%, consistent with severe
The document discusses guidelines for managing chronic obstructive pulmonary disease (COPD). It describes COPD as a chronic inflammatory lung disease characterized by airflow limitation. The guidelines recommend treatments based on COPD severity, including bronchodilators and inhaled corticosteroids. Ongoing research is exploring new drugs and combinations to better treat COPD and reduce exacerbations.
This document discusses long-term oxygen therapy (LTOT) and home oxygen therapy. It provides an overview of the terminology, scientific background, equipment, indications, and practical considerations of LTOT. It also includes two case studies examining whether a patient should start or continue LTOT. The document summarizes the effects of LTOT including improved survival, decreased hospitalizations, and improved quality of life for COPD patients. It addresses portable oxygen therapy and the prevalence of home oxygen therapy in different countries.
This document discusses long-term oxygen therapy (LTOT). It provides an overview of the terminology, scientific background, equipment, indications, and quality of LTOT treatment. Specifically:
1) It defines various types of home oxygen therapy including LTOT, short-term oxygen therapy (STOT), ambulatory oxygen therapy, and oxygen used for palliation of attacks of dyspnea.
2) It reviews studies showing the effects of LTOT on survival, health outcomes, and hospitalizations for COPD patients. LTOT is shown to increase survival by 2-4 years and decrease hospitalizations by 25% for qualifying patients.
3) It discusses considerations for starting, controlling, and ensuring quality of LT
1. The impact of a national oxygen register on the
adherence to guidelines for LTOT in COPD patients
Thomas Ringbæk, Hvidovre Hospital
Peter Lange, Hvidovre Hospital
2. Background:
Several studies have shown poor quality of
LTOT in COPD pts.
Aims of this study:
Has a national oxygen register any impact on
adherence to guidelines for LTOT:
-administration >15 hrs daily
-follow up 1-6 months after start
-no smoking
-hypoxaemia documented
Changes in prevalence, incidence, patients´
characteristics, oxygen devices, and survival
4. The Danish Oxygen Register
established Nov. 1994
The Danish
Oxygen Register
Oxygen
suppliers
Patients´
questionnaire
Central Board of
statistics
Patients´ files
1. year
Use of O2
Subjective effect
Smoking status
Flow
Hrs/day
Oxygen devices
Responsible for LTOT
Possible stop
1. year
Diagnosis
Lung function
Blood gases
Smoking status
Diagnosis
Hospitalisation
Vital status
5. Covers 99% of all
Danes (5.3 mill.)
17.658 on LTOT
8.487 with COPD
6. Dissemination of data from
The Danish Oxygen Register
Meetings
Papers
Feedback to doctors on
request
9. Changes in patients´ characteristics,
prescription of LTOT, and delivered devices
in the period 1995 to 2000
0
10
20
30
40
50
60
70
80
90
1995 1996 1997 1998 1999 2000
%
Initiated after
admission
Outpatient clinic 1-6
months after start
Started by GP
0
10
20
30
40
50
60
70
01.11.9431.12.9531.12.9631.12.9731.12.9831.12.9931.12.00
%
Females
Age>70 yrs
Flow >1.5 L/minute
0
10
20
30
40
50
60
70
80
90
100
01.11.9431.12.9531.12.9631.12.9731.12.9831.12.9931.12.00
%
Oxygen
concentrator or
liquid oxygen
15-24 hrs/day
Mobile oxygen
10. Smoking status of COPD patients, residing in the central part
of Copenhagen, and on LTOT in 1995 and 2000, respectively.
0
10
20
30
40
50
60
70
80
asked yes,
smoking
CO
measured
high CO asked or
checked
smokers
1995, n= 240
2000, n= 279
p>0.05
11. Hypoxaemia status*.
Data from the central part of Copenhagen
Nov. 1994 31.12.2000
N=145 N=214
83%
15%
2%
72%
16%
12%
Hypoxaemic
Normoxaemic
Missing
P=0.018*) PO2 <7.3 kPa or 7.3-8.0 kPa
+ clinical signs of chronic hypoxaemia
All Danes: 57.5%
12. Survival rates of new COPD patients on LTOT from
Denmark compared to patients from other countries
0
10
20
30
40
50
60
70
80
90
100
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Months
Cumulativesurvivalproportion(%)%)
Denmark (n=5659)
Sweden (n=403)
Belgium (n=270)
France (n=252)
Australia (n=505)
NOTT, COT (n=101)
Japan (n=4552)
13. Survival of COPD patients who
started LTOT in 1995 versus 1999
0,00 0,50 1,00 1,50 2,00 2,50 3,00 3,50 4,00 4,50 5,00 5,50 6,00
Years
0,0
0,2
0,4
0,6
0,8
1,0
CumSurvival
Year of start
1995
1999
Median
1.07 vs
1.40 yrs;
p=0.032
14. Conclusion (1)
↑ incidence and prevalence of COPD
(to 27 and 42 per 100.000)
↑ mobile oxygen
↑ started after hospitalisation
↑ age
↑ ”15-24 hrs/day”
15. Conclusion (2)
Only about 50% are followed up
↑ documented hypoxaemia
At least 20-25% are still smoking
↓ survival compared to other countries
↑ survival over time
Not optimal utilization of data.
Direct access to own data or current feedback?
According to the title of our presentation, I will present data on adherence to guidelines for COPD patients on LTOT in the period 1994-2000. Secondly, I present data on diagnosis ect. in this study period.
Inspired by the Swedish and French Oxygen Register, we established The Danish Oxygen Register Nov. 1994.
The oxygen suppliers: All patients on LTOT. Flow, hours daily, systems, doctor prescr.
The first year all patients where asked to answer a questionnaire about use of oxygen, smoking, and the subjective effect of oxygen.
From the files we got information on diagnosis, lung function, blood gases etc.
Central Board of Statistics: Vital status and hospitalisation
The Register covers nearly all Danes on LTOT.
In the study period, more than 17.000 patients had been registered,
And about half of these had COPD.
The data was diss. Through meetings – local as well as national
Through papers – in Danish and international
And feedback to doctors on request
In 1994 the prevalence was about 27/100.000. I the following years, it increased by about 50% to 42/100.000
New COPD patients on LTOT. A smaller increase was seen for the incidence.
About 60% of the COPD patients were females with no change over time.
Age and flow increased significantly.
Sign. increases were seen in delivered oxygen concentrators/liquid oxygen, prescribed oxygen 15-24 hrs daily, and delivered mobile oxygen.
These trends were also seen for new patients.
For new patients, we observed that most started right after a hospitalisation when they were clinically unstable, and this number increased.
Only about half of the patients who had LTOT after 6 months had been seen in the out-patient clinic. Unfortunately, without any improvement over time.
Fewer patients had LTOT started by a GP.
In a sub sample of COPD pts. on LTOT, residing in the central part of CPH and comprising about 15% of all COPD pts on LTOT in Denmark, smoking status was examined in 1995 and 2000.
-about 75% of the pts were asked about smoking.
-nearly 20% admitted that they smoked
-a little more than 50% had carbon monooxide measured – either in the blood or in the expired air.
-about 15% had too high level
-when the questionnaire and CO-test were combined, nearly 80% were examined.
-and 20-25% were considered current smokers.
No changes over time were seen.
In 1994, the same figures were seen for all COPD pts. on LTOT in Denmark.
In the same sub sample of patients, hypoxaemic status was examined in 1994 and 2000.
In 1994, 72% of the pts had hypoxaemia detected, and this figure increased significantly to 83% in 2000.
However, this sub sample was not representative fo all patients in Denmark. In 1994, 57.5% of all pts. Had hypoxaemia detected.
Compared with the rest of the country, most of the patients in CPH had LTOT prescribed by a chest physician.
Our COPD patients had worse survival compared to other countries. Especially high 6-month mortality rate was seen in our patients. It is difficult to explain this. In our study, the number of patients who started LTOT right after a hospitalisation was very high, and these patients had higher mortality than patients who started LTOT in the out-patient clinic.
In the NOTT study all pts. And, I believe, in the Swedish study most of the pts. had LTOT prescribed in a clinical stable condition.
In the study period, the median survial time was increased by 4 months – about 30%.
So far, the utilization of data from this oxygen register has not been optimal. Direct access to own data and current feedback on adherence to guidelines for COT may improve the quality. This has been practiced in patients with hernia surgery. Two and an half year after implementation of The Danish Hernia Database, the quality of operation improved significantly (109). From this database, feedback was provided to participants twice yearly, with the results for the specific participant compared with the entire database.